Related Experiment Videos
Refractory sarcoidosis responding to infliximab
Scott D Roberts1, David S Wilkes, Richard A Burgett
1Department of Medicine, Pulmonary Division, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Chest
|November 8, 2003
Summary
Tumor necrosis factor (TNF)-alpha inhibitors show promise for treating severe sarcoidosis. A patient with refractory sarcoidosis experienced significant improvement in eye and skin symptoms after receiving infliximab, an anti-TNF antibody.
Area of Science:
- Immunology
- Rheumatology
- Pulmonology
Background:
- Sarcoidosis is an inflammatory disease characterized by granuloma formation, often affecting multiple organs.
- Conventional therapies can be insufficient for progressive or debilitating cases of sarcoidosis.
- Tumor necrosis factor-alpha (TNF-alpha) plays a key role in granulomatous inflammation.
Observation:
- A patient presented with refractory sarcoidosis involving the lungs, eyes, skin, and heart.
- The condition worsened despite aggressive conventional treatment.
- Oculocutaneous manifestations were particularly severe.
Findings:
- Treatment with infliximab, an antibody targeting TNF-alpha, led to dramatic improvement.
- The patient's ocular and cutaneous sarcoidosis responded positively to anti-TNF therapy.
- This suggests a potential therapeutic role for TNF-alpha inhibition in severe sarcoidosis.
Implications:
- Infliximab may be a viable treatment option for refractory sarcoidosis, especially for oculocutaneous involvement.
- Targeting TNF-alpha could offer a new therapeutic strategy for debilitating inflammatory conditions like sarcoidosis.
- Further research is warranted to evaluate the efficacy and safety of anti-TNF agents in sarcoidosis management.